https://www.selleckchem.com/products/wm-8014.html
027). On Cox proportional hazards analysis, cancer cachexia was significantly associated with shorter OS. The incidence of adverse events did not differ between the two groups. Nivolumab was associated with better OS and TTF outcomes in AGC patients without cachexia than in those with cachexia, albeit there was no difference in the incidence of adverse events. Cancer cachexia may be associated with worse clinical outcomes in patients with AGC treated with nivolumab. Cancer cachexia may be associated with worse clinical outcomes in patie
Like
Comment
Share
